DSL-021 Risk Analysis of Medicines Produced in Hospital Pharmacy – a Tool For Ensuring Optimal Supply. (12th March 2013)

• Record Type: Journal Article
• Authors: Schmidt-Petersen, L; Jensen, L; Dinsen-Andersen, C
• Is Part Of: European journal of hospital pharmacy. Volume 20(2013)Supplement 1
• Page Start: A94
• Page End: A94
• Publication Date: 2013-03-12
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2013-000276.264
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background: The hospital pharmacy unit for the preparation of licenced sterile medicines manufactures 110 different extemporaneous preparations and licenced medicines for injection or infusion. This unit needs a tool for production planning i.e. an assessment of which medicines are critical and hence must always be in stock. Purpose: To create a tool for risk assessments for all medicines manufactured in the unit, enabling appropriate prioritising of resources from a treatment perspective. Materials and Methods: All risk assessments are executed and stored in SAID (National question and answer database). The advantages of this method are that each risk assessment is quality assured and acts as a dynamic document that can be updated regularly. Risk assessments are based on relevant literature (e.g. Summary of Product Characteristics and Micromedex). For each risk assessment the following is examined as a minimum: Which patient group will benefit from the medicine? Therapeutic indications and administration Are there any alternative treatments? Does a synonymous/analogous medicine exist? Any safety concerns regarding method of administration? Can the manufacturers maintain the flow of supply? Based on the above the risk assessments are allocated a score 1 to 5, which indicates the severity of a back order. Results: The risk assessments were distributed as follows: 18% scored 5 (no alternative medicine exists) 38% scored 4 (analogous medicine exists) 24% scored 3 (synonymous extemporaneous or non-licenced medicine exists) 9% scored 2 (synonymous medicine exists) 11% scored 1 (more than one analogue/synonym exists) The risk assessments showed that none of the medicines could be dispensed from a treatment perspective. Shorter periods of back order of some medicines can be tolerated with no effect of patient care and safety, if alternative synonyms/analogous medicines are supplied from other manufacturers. Conclusions: Risk assessments have given the unit a tool for production planning and prioritising the manufacturing of medicines. No conflict of interest.